The DNA microarray market is projected to grow from USD 2.73 billion in 2025 to over USD 6.13 billion by 2034, driven by a CAGR of 9.43%. Rising prevalence of genetic disorders, increasing demand for personalized medicine, and advancements in genomics research are fueling this growth. North America leads the market, while Asia-Pacific is expected to grow fastest. Innovations in customized microarrays and omics integration are creating new opportunities across clinical and research applications.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: DNA Microarray Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. DNA Microarray Market, by Type
8.1.1 Complementary DNA Microarrays
8.1.1.1. Market Revenue and Forecast
8.1.2. Oligonucleotide DNA Microarrays
8.1.2.1. Market Revenue and Forecast
8.1.3. Others
8.1.3.1. Market Revenue and Forecast
9.1. DNA Microarray Market, by Application
9.1.1. Gene Expression Analysis
9.1.1.1. Market Revenue and Forecast
9.1.2. Genotyping
9.1.2.1. Market Revenue and Forecast
9.1.3. Others
9.1.3.1. Market Revenue and Forecast
10.1. DNA Microarray Market, by End-user
10.1.1. Pharmaceutical and Biotechnology Companies
10.1.1.1. Market Revenue and Forecast
10.1.2. Diagnostic Centers
10.1.2.1. Market Revenue and Forecast
10.1.3. Hospitals and Clinics
10.1.3.1. Market Revenue and Forecast
10.1.4. Academic and Research Institute
10.1.4.1. Market Revenue and Forecast
10.1.5. Others
10.1.5.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Type
11.1.2. Market Revenue and Forecast, by Application
11.1.3. Market Revenue and Forecast, by End-user
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Type
11.1.4.2. Market Revenue and Forecast, by Application
11.1.4.3. Market Revenue and Forecast, by End-user
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Type
11.1.5.2. Market Revenue and Forecast, by Application
11.1.5.3. Market Revenue and Forecast, by End-user
11.2. Europe
11.2.1. Market Revenue and Forecast, by Type
11.2.2. Market Revenue and Forecast, by Application
11.2.3. Market Revenue and Forecast, by End-user
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Type
11.2.4.2. Market Revenue and Forecast, by Application
11.2.4.3. Market Revenue and Forecast, by End-user
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Type
11.2.5.2. Market Revenue and Forecast, by Application
11.2.5.3. Market Revenue and Forecast, by End-user
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Type
11.2.6.2. Market Revenue and Forecast, by Application
11.2.6.3. Market Revenue and Forecast, by End-user
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Type
11.2.7.2. Market Revenue and Forecast, by Application
11.2.7.3. Market Revenue and Forecast, by End-user
11.3. APAC
11.3.1. Market Revenue and Forecast, by Type
11.3.2. Market Revenue and Forecast, by Application
11.3.3. Market Revenue and Forecast, by End-user
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Type
11.3.4.2. Market Revenue and Forecast, by Application
11.3.4.3. Market Revenue and Forecast, by End-user
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Type
11.3.5.2. Market Revenue and Forecast, by Application
11.3.5.3. Market Revenue and Forecast, by End-user
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Type
11.3.6.2. Market Revenue and Forecast, by Application
11.3.6.3. Market Revenue and Forecast, by End-user
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Type
11.3.7.2. Market Revenue and Forecast, by Application
11.3.7.3. Market Revenue and Forecast, by End-user
11.4. MEA
11.4.1. Market Revenue and Forecast, by Type
11.4.2. Market Revenue and Forecast, by Application
11.4.3. Market Revenue and Forecast, by End-user
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Type
11.4.4.2. Market Revenue and Forecast, by Application
11.4.4.3. Market Revenue and Forecast, by End-user
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Type
11.4.5.2. Market Revenue and Forecast, by Application
11.4.5.3. Market Revenue and Forecast, by End-user
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Type
11.4.6.2. Market Revenue and Forecast, by Application
11.4.6.3. Market Revenue and Forecast, by End-user
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Type
11.4.7.2. Market Revenue and Forecast, by Application
11.4.7.3. Market Revenue and Forecast, by End-user
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Type
11.5.2. Market Revenue and Forecast, by Application
11.5.3. Market Revenue and Forecast, by End-user
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Type
11.5.4.2. Market Revenue and Forecast, by Application
11.5.4.3. Market Revenue and Forecast, by End-user
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Type
11.5.5.2. Market Revenue and Forecast, by Application
11.5.5.3. Market Revenue and Forecast, by End-user
12.1. Thermo Fisher Scientific Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Agilent Technologies, Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Illumina, Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. PerkinElmer, Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Bio-Rad Laboratories, Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Roche Diagnostics
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Qiagen N.V.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Oxford Gene Technology (OGT)
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Applied Microarrays, Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Eurofins Genomics LLC
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description